For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Corteva Inc. (CTVA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -24 (−100…+100 Quality+Value blend) · Quality 36 · Value -73 · Sentiment 0 (timing only, not weighted) · Composite fair value $36.06 vs $76.68 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Corteva Inc.
CTVA NYSECorteva Inc. is an agricultural inputs company that provides seed and crop protection solutions to farmers and agricultural businesses worldwide. The company focuses on improving crop productivity and protecting yields through a broad portfolio that includes advanced seeds, herbicides, insecticides, fungicides, seed treatments, and nitrogen management products. Its offerings support a range of major crops and are used across row-crop and specialty agriculture markets. Corteva Inc. plays an important role in the global food supply chain by helping growers manage pests, disease, and weed pressure while supporting more efficient farm operations. Headquartered in Indianapolis, Indiana, Corteva Inc. operates as a dedicated agriscience business with products and services tailored to modern agriculture.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 1.60
Total Equity: $24.39B
Shares: 681,400,000
Total Debt: $894.00M
Cash: $4.52B
EBITDA: $4.47B
Total Debt: $894.00M
Cash: $4.52B
Revenue: $17.40B
Revenue: $17.40B
Revenue: $17.40B
Total Equity: $24.39B
Tax Rate: 28.7%
Equity: $24.39B
Total Debt: $894.00M
Cash: $4.52B
Current Liabilities: $12.13B
Long-Term Debt: $0.00
Total Debt: $894.00M
Total Equity: $24.39B
Shares: 681,400,000
Shares: 681,400,000
CapEx: $0.00
Shares: 681,400,000
Stock Price: $76.66
Net Income: $1.09B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 16, 2026 12:31am (7d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $15.7B | $17.5B | $17.2B | $16.9B | $17.4B |
| Cost of Revenue | $9.2B | $10.4B | $9.9B | $9.5B | $9.2B |
| Gross Profit | $6.4B | $7.0B | $7.3B | $7.4B | $8.2B |
| Operating Expenses | $4.4B | $4.4B | $4.5B | $4.6B | $5.0B |
| Operating Income | $2.0B | $2.6B | $2.8B | $2.8B | $3.3B |
| Net Income | $1.8B | $1.1B | $735.0M | $907.0M | $1.1B |
| EBITDA | $3.3B | $3.9B | $4.0B | $4.0B | $4.5B |
| EPS | $2.39 | $1.59 | $1.04 | $1.31 | $1.60 |
| EPS (Diluted) | $2.37 | $1.58 | $1.03 | $1.30 | $1.60 |
Balance Sheet (Annual)
Last updated: Aug 16, 2026 12:12am (7d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.5B | $3.2B | $2.6B | $3.1B | $4.5B |
| Total Current Assets | $15.5B | $16.8B | $16.3B | $15.1B | $17.3B |
| Total Assets | $42.3B | $42.6B | $43.0B | $40.8B | $42.8B |
| Current Liabilities | $9.6B | $10.7B | $10.4B | $10.4B | $12.1B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $16.7B | $17.1B | $17.7B | $16.8B | $18.5B |
| Total Equity | $25.6B | $25.5B | $25.3B | $24.0B | $24.4B |
| Retained Earnings | $524.0M | $250.0M | -$41.0M | $55.0M | -$67.0M |
Cash Flow (Annual)
Last updated: Aug 16, 2026 12:31am (7d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.7B | $872.0M | $1.8B | $2.1B | $3.4B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | $0 | $0 | -$1.5B | $0 | $0 |
| Net Debt Issued / (Repaid) | $11.0M | $205.0M | $1.1B | $240.0M | -$141.0M |
| Dividends Paid | $397.0M | $418.0M | -$439.0M | -$458.0M | -$475.0M |
| Stock Buybacks | -$950.0M | -$1.0B | -$756.0M | -$1.0B | -$1.1B |
| Net Change in Cash | $963.0M | -$1.2B | -$460.0M | $264.0M | $1.3B |
Growth Trends (YoY %)
Last updated: Aug 16, 2026 12:31am (7d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +11.5% | -1.3% | -1.8% | +2.9% |
| Gross Profit Growth | +9.1% | +4.1% | +1.0% | +11.5% |
| Operating Income Growth | +29.0% | +6.2% | -0.4% | +17.3% |
| Net Income Growth | -34.8% | -35.9% | +23.4% | +20.6% |
| EBITDA Growth | +17.4% | +3.9% | +0.1% | +11.4% |
Dividend History (Last 20)
Last updated: Aug 11, 2026 12:57pm (12d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-01 | $0.18 | — | — | — |
| 2026-03-02 | $0.18 | — | — | — |
| 2025-12-01 | $0.18 | — | — | — |
| 2025-09-02 | $0.18 | — | — | — |
| 2025-06-02 | $0.17 | — | — | — |
| 2025-03-03 | $0.17 | — | — | — |
| 2024-12-02 | $0.17 | — | — | — |
| 2024-09-03 | $0.17 | — | — | — |
| 2024-06-04 | $0.16 | — | — | — |
| 2024-02-29 | $0.16 | — | — | — |
| 2023-11-30 | $0.16 | — | — | — |
| 2023-08-31 | $0.16 | — | — | — |
| 2023-05-31 | $0.15 | — | — | — |
| 2023-02-28 | $0.15 | — | — | — |
| 2022-11-10 | $0.15 | — | — | — |
| 2022-08-11 | $0.15 | — | — | — |
| 2022-05-12 | $0.14 | — | — | — |
| 2022-02-28 | $0.14 | — | — | — |
| 2021-11-10 | $0.14 | — | — | — |
| 2021-08-12 | $0.14 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-23 02:52Even the bull case prices 60% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 78%.
| Case | Growth | Margin | Fair value | vs price ($76.68) |
|---|---|---|---|---|
| Bull — recovery | +3% | 9.2% | $30.75 | -60% |
| Base — stabilizes | +2% | 8.0% | $26.10 | -66% |
| Bear — keeps slipping | +1% | 6.8% | $21.73 | -72% |
| Stress — last quarter repeats | -2% | 5.7% | $16.78 | -78% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-16AI-driven genomic prediction and phenotype analysis shorten the breeding cycle and raise hit rates on trait and molecule discovery — a gain that accrues disproportionately to whoever owns the largest labeled germplasm and multi-season field-trial dataset, which Corteva does.
AI-enabled precision application (see-and-spray, variable-rate prescriptions) reduces chemical volume per acre, and the crop protection segment is monetized in gallons; the same models let generics and biologicals compete on 'good enough' efficacy at lower rates.
Whether AI shows up as more value captured per seed bag (royalties, trait premiums, mix shift to seed) or as fewer gallons of crop protection sold. Watch segment-level volume vs price in crop protection against seed royalty and trait licensing revenue.
Proprietary germplasm libraries, multi-decade genotype-to-field-yield datasets across global environments, active substance registrations, and a physical multi-country field-trial and distribution network — none of which cheap software creates.
AI Lens thesis
AI reaches Corteva through R&D productivity and through the customer's spray boom, not through its interface. The need — protecting yield — is permanent and physical; the seed itself cannot be downloaded, and no grower wants to own hybrid breeding or pesticide registration liability, so DIY and disintermediation risk is low. The favorable channel is that design intelligence becomes abundant while the scarce complements Corteva controls (elite germplasm, labeled multi-environment trial data, registered actives, dealer reach) become relatively rarer and more valuable, compressing years off discovery timelines. The unfavorable channel is that the monetized unit in roughly half the business is volume of chemistry, and AI's most commercially proven farm application is using less of it more precisely, while AI plus gene editing lowers the technical, though not regulatory, cost of new trait entrants. Net: structurally mildly positive with a real mix problem beneath it.
What the market may be underestimating
Upside Corteva's out-licensing model turns AI-accelerated trait discovery into royalty income with almost no incremental capital — a high-margin, non-volume revenue unit that is immune to precision-application erosion and helps explain the 41%→47% gross margin path.
Downside AI-driven agronomic prescription platforms owned by equipment makers and ag retailers can become the decision layer that specifies which chemistry goes on the acre, converting Corteva's branded recommendation into a commoditized spec-fill order at the point of maximum price sensitivity.
Outcome range spread 40
Growth Outlook
Analyzed 2026-08-17 16:25The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
ai-findings step) when a report is run on this ticker.
GPT Reading
Corteva looks expensive if you anchor on the headline P/E, but the raw operating data argue that the earnings denominator is still distorted by seasonality, restructuring/noise, and a business mix that has quietly improved. Revenue has gone essentially nowhere over four years — $17.46B in 2022, $17.23B in 2023, $16.91B in 2024, then back to $17.40B in 2025 — so this is clearly not a volume-growth story. What has changed is profitability quality. Gross profit rose from $6.44B in 2021 to $8.23B in 2025 on only $1.7B of incremental sales over that span, lifting gross margin from about 41% to 47.3%. Operating income climbed from $2.04B to $3.26B, and operating margin from 13.0% to 18.8%. That is a major structural shift for an agricultural inputs business, and it matters more than the superficial “stagnant revenue” critique. The first half of 2026 reinforces that: revenue of $11.29B versus $10.88B in 1H25, with net income of $1.88B versus $1.96B a year earlier. On sales growth of just 3.8%, Q2 still printed a very healthy 18.2% net margin. This is a company proving it can defend high profitability even without a booming farm cycle.
The balance sheet and cash generation also deserve more credit than the valuation models seem to give. With just $894M of debt against $4.52B of cash, Corteva is in a net cash position of roughly $3.6B. Debt-to-equity is 0.04, current ratio 1.43, and operating cash flow was $3.41B in 2025 against only $1.09B of net income, which tells you accounting earnings understate cash conversion rather than flatter it. A business producing $3B+ of operating cash with a fortress balance sheet does not deserve to be valued like a no-growth chemical cyclical with balance-sheet risk. EV/EBITDA of 10.9x is much more informative than 47.9x P/E here, because the net income line has been unusually noisy while the operating line has been steadily improving. At $51.2B market cap, investors are paying a premium, but not an insane one, for a de-risked oligopolistic franchise with demonstrated margin expansion and strong cash resiliency.
My read is that the stock is closer to fairly valued-to-modestly rich than dramatically overvalued. The $42 fair value outputs strike me as too punitive because they seem to extrapolate low top-line growth without giving enough credit to the step-change in gross and operating margins. If Corteva can sustain something near 18% operating margin on a $17.5B-$18.0B revenue base, then operating earnings power is already north of $3B, and normalized net income should be materially better than the trailing $1.09B that drives the scary P/E. The quarterly pattern makes that obvious: 2025 had two strong profit quarters, two seasonal loss quarters, and full-year net income that looks depressed relative to operating performance. The market is not paying for explosive growth; it is paying for durable pricing power, mix improvement, and low financial risk. I would not call that cheap at $76.68, but I also would not short a business with this margin trajectory and balance sheet strength.
The best counterargument is straightforward and serious: revenue is flat, ROE is only 4.5%, net margin is just 6.3% on the annual numbers, and the latest four reported quarters sum to only about $1.01B of net income, which still leaves the stock trading around 50x trailing earnings. A skeptic would say this is exactly how investors get trapped in “quality cyclicals” — they capitalize peak or normalized margins while ignoring that farmer economics are inherently cyclical and input pricing power can crack fast. They would also point to 1H26 net income being down from $1.96B to $1.88B despite higher revenue, suggesting margin expansion may already be plateauing. That is all fair, and it is why I am not bullish enough to call this undervalued. I weigh it differently because the operating evidence over multiple years shows improvement at the gross and EBIT level, not just a one-quarter spike, and because the balance sheet removes a lot of downside reflexivity that usually punishes cyclical inputs names.
What would change my mind is pretty specific. If full-year 2026 revenue stalls near $17.4B again but operating margin slips back toward 16% and operating cash flow drops materially below $3B, then the premium multiple is unjustified and I would move bearish quickly. Likewise, if the back half of 2026 shows the seasonal loss quarters deepening back toward 2024 levels — for example Q3/Q4 combined losses worse than the roughly $872M seen in 2025 — that would suggest the margin story is not durable. On the other hand, if Corteva converts the 1H26 pace into roughly $17.9B-$18.2B of annual revenue while holding operating margins near 18% and lifting annual net income meaningfully above $1.5B, then today’s price would look reasonable and possibly cheap.
Grok Reading
The numbers describe a high-quality but mature agricultural inputs franchise being valued like a growth compounder. Corteva generated $17.40B in 2025 revenue—only 2.9% above the prior year and essentially flat versus the $17.46B peak in 2022—yet the stock trades at 47.9x trailing earnings and 3.0x sales. Net income recovered to $1.09B from the 2023 trough of $735M, and gross margin has climbed to 47.3% from the low-40s five years earlier, lifting operating margin to 18.8%. That mix shift toward seeds and higher-value chemistries is real and visible in the first-half 2026 run-rate ($6.38B revenue, 18.2% net margin in Q2). The balance sheet is fortress-like: $4.52B cash against $894M debt, debt-to-equity of 0.037, and operating cash flow of $3.41B. None of that justifies a mid-40s earnings multiple when revenue CAGR sits at 0.5% and ROE is a meager 4.5%. The market is paying an 80% narrative premium for oligopoly pricing power and secular food-demand optionality that has not yet translated into top-line acceleration.
Seasonality is extreme and must be read carefully. Q3 and Q4 routinely post losses (–$320M and –$552M in the back half of 2025), so trailing twelve-month earnings compress and inflate the reported PE. Even annualizing the stronger first-half run-rate leaves the shares expensive relative to any normalized mid-cycle earnings power near $2.00–$2.50 per share. EV/EBITDA of 10.9x looks less offensive, but that metric benefits from the same margin expansion that is already largely reflected in the price; further multiple expansion requires the biologics and digital tools story to start moving the revenue needle, which the 0.5% CAGR and low-single-digit recent growth simply do not show. Insider activity is pure award and tax-withholding noise—no open-market conviction either way.
The strongest counter-argument is that the earnings trough is behind us and the seed oligopoly can sustain pricing even when farm incomes are stressed. Gross margin expansion of roughly 600 basis points over five years, FCF CAGR near 39%, and a net-cash balance sheet give the company real optionality to buy back stock or invest through the cycle. A smart bull would also note that EV/revenue of 2.8x and a sub-11x EV/EBITDA are not outrageous for a business with 47% gross margins and limited capital intensity, and that any re-acceleration in planted acres or crop prices would drop straight through to an already-levered earnings base. I weigh this less heavily because the current 48x PE and $76.66 price already embed that recovery plus continued mix upgrade; the 2025 net margin is still only 6.3%, and farm economics remain the binding constraint the thesis evaluation correctly flags.
I would reverse to a neutral or constructive stance if the next two full years delivered sustained mid-single-digit or better organic revenue growth alongside operating margins pushing through 22%, or if management disclosed biologics/digital contribution large enough to prove the platform narrative is becoming a material P&L driver rather than a slide-deck aspiration. A decisive break in the seed pricing umbrella or another leg down in farm income that reversed the gross-margin gains would confirm the overvaluation more forcefully.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Corteva is a mature agricultural inputs business generating consistent free cash flow (2.82B run-rate, 3.41B in 2025) on roughly flat revenue in the 16.9-17.5B range across 2021-2025. Gross margin has expanded meaningfully from 41.1% to 47.3% and operating margin from 13% to 18.8% over five years - a real, sustained operating-leverage story that suggests either mix improvement, pricing power in seeds/crop protection, or cost discipline. Earnings quality is clean: OCF/NI of 2.04x, negative accruals (-2.5% of assets), Beneish M of -2.73, and no mechanical red flags.
Verify before trusting this (6)
- Reconciliation of 18.8% operating margin to ~6.3% net margin - what non-operating items (interest, restructuring, litigation, tax) are compressing NI
- Segment split between Seed and Crop Protection and whether margin expansion is driven by one segment or both
- Customer/geographic concentration and exposure to LatAm/Brazil ag cycle
- Pension and legacy DuPont-spin liabilities that could explain the OpM-to-NI gap
- Buyback pace and authorization remaining - is the -2.1% share CAGR set to continue
- R&D spend trajectory and pipeline for seed traits/biologicals underpinning pricing
Price is $76.68 against a composite FV of $38.70 and a signal-adjusted FV of $42.25 - implying roughly -45% downside if you believe the models. Even the most generous internal method, the EPV floor at $45.96, leaves the stock ~40% above deserved value, and the anchored-PE read of $31.43 is far below that. The Quality lens rightly flags a solid, cash-generative mature earner with real margin expansion and buybacks, which supports paying up - but not paying nearly 2x the EPV floor.
Verify before trusting this (5)
- Segment operating margin trajectory in Seed vs Crop Protection
- Reconciliation of operating income to net income (what sits below the line causing the jumpiness)
- FY guidance on organic growth and pricing vs volume mix
- Buyback pace and capital return plan
- Any one-off gains inflating recent net income
The macro tape is mildly supportive: VIX at 14.3, S&P near highs, regime risk-on for 10 days. But CTVA's 0.57 beta means the tape barely lifts it - it neither rips higher on risk appetite nor gets mauled on wobbles. The active narrative is a strong platform-monopoly story (integrated seed-and-chemistry, trait lock-in, biologics optionality) with moderate durability and low cult following, which has already carried price to a large premium versus DCF. That is the key pressure: the story is doing the heavy lifting, not flows or macro. News flow is thin and constructive - microbial inoculants coverage reinforces the biologics angle - and there is no visible narrative crack in the last 72 hours. Analyst tone is not screaming either way. Net, sentiment is a slight tailwind from tape and intact narrative, offset by the fragility of a strong-intensity story with only moderate durability sitting on a rich multiple. Low beta and defensive-adjacent ag exposure blunt macro headwinds from 4.63% 10y and a 26.2 market PE, so this name is less a sentiment trade and more a story-integrity trade. Pressure is real but not decisive in either direction.
Verify before trusting this (5)
- Any analyst target revisions or downgrades citing valuation stretch
- Farmer income and planting-intention data that could crack the pricing-power story
- Biologics/digital ag revenue traction in next print - the pillar holding the premium
- Whether ag-inputs peers (FMC, MOS, NTR) start diverging, signaling sector rotation
- VIX break above 18 or S&P off highs - would test the low-beta shield
AI reaches Corteva through R&D productivity and through the customer's spray boom, not through its interface. The need — protecting yield — is permanent and physical; the seed itself cannot be downloaded, and no grower wants to own hybrid breeding or pesticide registration liability, so DIY and disintermediation risk is low. The favorable channel is that design intelligence becomes abundant while the scarce complements Corteva controls (elite germplasm, labeled multi-environment trial data, registered actives, dealer reach) become relatively rarer and more valuable, compressing years off discovery timelines. The unfavorable channel is that the monetized unit in roughly half the business is volume of chemistry, and AI's most commercially proven farm application is using less of it more precisely, while AI plus gene editing lowers the technical, though not regulatory, cost of new trait entrants. Net: structurally mildly positive with a real mix problem beneath it.
None surfaced.
Verify before trusting this (8)
- Global planted acreage trends
- Resistance pressure driving new chemistry demand
- Farm income and input affordability
- Germplasm licensing terms and rates
- Field-trial footprint investment
- Trait royalty income growth
- Crop protection volume trend ex-destocking
- Price per acre versus gallons sold
Global calorie demand keeps acres planted, so this is not a demand-destruction story — it is a pricing story. Post-destocking crop protection is being re-rated downward permanently by Chinese generic supply, which caps the chemistry half of ag inputs. Value is migrating to genetics and traits, where intellectual property still sets price and where Corteva's own stacks are displacing licensed ones. Meanwhile farmer profitability is thin at current grain prices, so the mix shift toward premium seed is slower than in a strong-price year. Net: a low-growth, deflation-tinged category in which the differentiated-seed owner can compound earnings faster than its revenue line for several more years, then must find a new engine.
When we made this prediction on Aug 16, 2026, CTVA was $76.68. We expect it to be $70.00 by Feb 2027, and we consider it great value under $50.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 16, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.